Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indobufen versus low-molecular-weight heparin for prevention of deep vein thrombosis after hip arthroplasty
ChiCTR-IPR-17013008Phase 4Recruiting
- Sponsor
- The Third Hospital of Hebei Medical University
- Start
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in deep vein thrombosis (DVT) comparing Indobufen cohort with Low molecular weight heparin cohort (2 cohorts). Primary endpoint: Incidence of deep vein thrombosis in both lower extremities. Started Oct 2016; status: recruiting.
02
Drugs
Indobufenlow molecular weight heparin calcium
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ChiCTR-IPR-17013008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013008.